Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) entered public markets through a de-SPAC merger with ARYA Sciences Acquisition Corp II, a 2020 blank-check vehicle sponsored by Perceptive Advisors. The S-1 registration statement filed November 25, 2020 formalized the business combination that brought the neuroscience-focused biopharmaceutical company — originally a Pfizer spinout backed by Bain Capital — to public markets. Cerevel's pipeline targeted neurological and psychiatric indications including schizophrenia, Parkinson's disease, and epilepsy. The combined entity traded under CERE on Nasdaq following closing of the transaction. AbbVie subsequently agreed to acquire Cerevel in a 2024 all-cash deal. For full filing history, sponsor profiles, and deal analytics on CERE and related SPAC vehicles, sign up for SpacDesk.